Combined PET-CT in the Head and Neck

Part 1. Physiologic, Altered Physiologic, and Artifactual FDG Uptake1
Published Online:

Positron emission tomography (PET) with 2-[fluorine-18] fluoro-2-deoxy-d-glucose (FDG) has been effective for the diagnosis, staging, and restaging of malignancies of the head and neck region. However, lack of anatomic landmarks, variable physiologic uptake, and asymmetric FDG distribution in several altered physiologic states can confound image interpretation. In addition, many benign causes and several artifacts can simulate physiologic or pathologic FDG uptake in the head and neck. Combined PET–computed tomography (CT) is a unique imaging modality that permits anatomic and functional imaging on a single scanner with nearly perfect coregistration. Combined PET-CT provides information that cannot be obtained with PET or CT alone. In particular, PET-CT facilitates the interpretation of FDG uptake in the head and neck, an area that is characterized by dense and complex anatomic structures. An atlas of FDG uptake in this anatomic region was compiled on the basis of combined PET-CT findings in 11,000 patients. In general, patterns of FDG uptake were variable and often reflected patient activity during or immediately preceding the uptake phase. With the growing interest in PET-CT, interpreting radiologists and nuclear medicine physicians must be familiar with the patterns of FDG uptake in the head and neck to avoid misinterpretation or mis-diagnosis.

© RSNA, 2005


  • 1 DizendorfEV, Baumert BG, Von Schulthess GK, Lutolf UM, Steinert HC. Impact of whole-body (18)F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med2003; 44: 24–29. MedlineGoogle Scholar
  • 2 HannahA, Scott AM, Tochon-Danguy H, et al. Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg2002; 236: 208–217. Crossref, MedlineGoogle Scholar
  • 3 LoweVJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol2000; 18:651–658. Crossref, MedlineGoogle Scholar
  • 4 HanasonoMM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope1999; 109:880–885. Crossref, MedlineGoogle Scholar
  • 5 FarberLA, Benard F, Machtay M, et al. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2–18F-fluoro-2-deoxy-d-glucose positron emission tomography. Laryngoscope1999; 109:970–975. Crossref, MedlineGoogle Scholar
  • 6 JabourBA, Choi Y, Hoh CK, et al. Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-d-glucose and MR imaging correlation. Radiology1993; 186:27–35. LinkGoogle Scholar
  • 7 ShrevePD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. RadioGraphics1999; 19:61–77. LinkGoogle Scholar
  • 8 BarringtonSF, Maisey MN. Skeletal muscle uptake of fluorine-18-FDG: effect of oral diazepam. J Nucl Med1996; 37:1127–1129. MedlineGoogle Scholar
  • 9 KinahanPE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys1998; 25:2046–2053. Crossref, MedlineGoogle Scholar
  • 10 AntochG, Freudenberg LS, Egelhof T, et al. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med2002; 43:1339–1342. MedlineGoogle Scholar
  • 11 GoerresGW, Hany TF, Kamel E, von Schulthess GK, Buck A. Head and neck imaging with PET and PET/CT: artefacts from dental metallic implants. Eur J Nucl Med Mol Imaging2002; 29: 367–370. Crossref, MedlineGoogle Scholar
  • 12 CookGJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med1996; 26:308–314. Crossref, MedlineGoogle Scholar
  • 13 GordonBA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. AJR Am J Roentgenol1997; 169:1675–1680. Crossref, MedlineGoogle Scholar
  • 14 LinEC. Thyroid nodule mimicking cervical ad-enopathy on FDG positron emission tomographic imaging. Clin Nucl Med2002; 27:656–657. Crossref, MedlineGoogle Scholar
  • 15 BornerAR, Voth E, Wienhard K, Wagner R, Schicha H. F-18-FDG PET in autonomous goiter. Nuklearmedizin1999; 38:1–6. Crossref, MedlineGoogle Scholar
  • 16 RamosCD, Chisin R, Yeung HW, Larson SM, Macapinlac HA. Incidental focal thyroid uptake on FDG positron emission tomographic scans may represent a second primary tumor. Clin Nucl Med2001; 26:193–197. Crossref, MedlineGoogle Scholar
  • 17 McDougallIR, Davidson J, Segall GM. Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun2001; 22:485–492. Crossref, MedlineGoogle Scholar
  • 18 StahlA, Dzewas B, Schwaiger M, Weber WA. Excretion of FDG into saliva and its significance for PET imaging. Nuklearmedizin2002; 41:214–216. Crossref, MedlineGoogle Scholar
  • 19 HoriuchiM, Yasuda S, Shohtsu A, Ide M. Four cases of Warthin’s tumor of the parotid gland detected with FDG PET. Ann Nucl Med1998; 12: 47–50. Crossref, MedlineGoogle Scholar
  • 20 MatsudaM, Sakamoto H, Okamura T, et al. Positron emission tomographic imaging of pleomorphic adenoma in the parotid gland. Acta Otolaryngol Suppl1998; 538:214–220. MedlineGoogle Scholar
  • 21 OkamuraT, Kawabe J, Koyama K, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of parotid mass lesions. Acta Otolaryngol Suppl1998; 538:209–213. MedlineGoogle Scholar
  • 22 ShihWJ, Ghesani N, Hongming Z, Alavi A, Schusper S, Mozley D. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin’s lymphoma of the parotid gland in a patient with Sjogren’s syndrome: before and after anti-CD20 antibody rituximab therapy. Clin Nucl Med2002; 27:142–143. Crossref, MedlineGoogle Scholar
  • 23 SagowskiC, Ussmuller J. Clinical diagnosis of salivary gland sarcoidosis (Heerfordt syndrome). HNO2000; 48:613–615. Crossref, MedlineGoogle Scholar
  • 24 KeyesJW Jr, Harkness BA, Greven KM, Williams DW 3rd, Watson NE Jr, McGuirt WF. Salivary gland tumors: pretherapy evaluation with PET. Radiology1994; 192:99–102. LinkGoogle Scholar
  • 25 Bar-ShalomR. Muscle uptake of 18-fluorine fluorodeoxyglucose. Semin Nucl Med2000; 30:306–309. Crossref, MedlineGoogle Scholar
  • 26 KostakogluL, Wong JC, Barrington SF, Cronin BF, Dynes AM, Maisey MN. Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med1996; 37:1771–1773. MedlineGoogle Scholar
  • 27 IgercI, Kumnig G, Heinisch M, Kresnik E, Mikosch P, Gallowitsch HJ, et al. Vocal cord muscle activity as a drawback to FDG-PET in the followup of differentiated thyroid cancer. Thyroid2002; 12:87–89. Crossref, MedlineGoogle Scholar
  • 28 ZhuZ, Chou C, Yen TC, Cui R. Elevated F-18 FDG uptake in laryngeal muscles mimicking thyroid cancer metastases. Clin Nucl Med2001; 26: 689–691. Crossref, MedlineGoogle Scholar
  • 29 CohadeC, Osman M, Pannu HK, Wahl RL. Uptake in supraclavicular area fat (“USA-Fat”): description on 18F-FDG PET/CT. J Nucl Med2003; 44:170–176. MedlineGoogle Scholar
  • 30 VirtanenKA, Peltoniemi P, Marjamaki P, et al. Human adipose tissue glucose uptake determined using [(18)F]-fluoro-deoxy-glucose ([(18)F]FDG) and PET in combination with microdialysis. Diabetologia2001; 44:2171–2179. Crossref, MedlineGoogle Scholar
  • 31 HanyTF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging2002; 29:1393–1398. Crossref, MedlineGoogle Scholar
  • 32 KamelEM, Goerres GW, Burger C, von Schulthess GK, Steinert HC. Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET-CT image fusion—report of six cases. Radiology2002; 224:153–156. LinkGoogle Scholar
  • 33 HellerMT, Meltzer CC, Fukui MB, et al. Super-physiologic FDG uptake in the non-paralyzed vocal cord: resolution of a false-positive PET result with combined PET-CT imaging. Clin Positron Imaging2000; 3:207–211. Crossref, MedlineGoogle Scholar
  • 34 StokkelMP, Bongers V, Hordijk GJ, van Rijk PP. FDG positron emission tomography in head and neck cancer: pitfall or pathology? Clin Nucl Med1999; 24:950–954. Crossref, MedlineGoogle Scholar
  • 35 KawabeJ, Okamura T, Shakudo M, et al. Physiological FDG uptake in the palatine tonsils. Ann Nucl Med2001; 15:297–300. Crossref, MedlineGoogle Scholar
  • 36 PuthenpurayilK, Blodgett TM, Meltzer CC. Photopenic defects in FDG PET scanning. AUR Annual Meeting, 2002. Google Scholar
  • 37 FukuiMB, Blodgett TM, Meltzer CC. PET/CT imaging in recurrent head and neck cancer. Semin Ultrasound CT MR2003; 24:157–163. Crossref, MedlineGoogle Scholar
  • 38 DizendorfEV, Treyer V, Von Schulthess GK, Hany TF. Application of oral contrast media in coregistered positron emission tomography-CT. AJR Am J Roentgenol2002; 179:477–481. Crossref, MedlineGoogle Scholar
  • 39 CarneyJP, Brasse D, Yap JT, Townsend DW. Clinical PET/CT scanning using oral CT contrast agents (abstr). J Nucl Med2002; 45:57. Google Scholar

Article History

Published in print: July 2005